168 related articles for article (PubMed ID: 26871834)
21. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
22. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.
Wang Y; Wang C; Xiao H; Niu C; Wu H; Jin H; Yao C; He H; Tian H; Han F; Li D; Han W; Xu J; Chen J; Cui J; Li W
Cancer Med; 2017 Jan; 6(1):45-53. PubMed ID: 27790867
[TBL] [Abstract][Full Text] [Related]
25. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
26. Prognostic value of blood lipids on patients treated with oxaliplatin combined with S-1 (SOX) after radical gastrectomy and establishment of prognostic nomogram.
Wang S; Chen C; Zhang J; Li J; Qin Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10293-10305. PubMed ID: 37270732
[TBL] [Abstract][Full Text] [Related]
27. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
Wang ZX; Yang XL; He MM; Wang F; Zhang DS; Li YH; Zhou ZW; Zhan YQ; Xu RH
Medicine (Baltimore); 2016 Apr; 95(16):e3214. PubMed ID: 27100411
[TBL] [Abstract][Full Text] [Related]
28. Adenocarcinoma of the gastric antrum: does D2 total gastrectomy with splenectomy improve prognosis compared to D1 subtotal gastrectomy? A long-term survival analysis with emphasis on Lauren classification.
Roukos D; Schmidt-Mathiesen A; Encke A
Surg Oncol; 1995; 4(6):323-32. PubMed ID: 8809955
[TBL] [Abstract][Full Text] [Related]
29. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
32. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
Liang Y; Zhao L; Chen H; Lin T; Chen T; Zhao M; Hu Y; Yu J; Liu H; Li G
BMC Cancer; 2021 Feb; 21(1):196. PubMed ID: 33632161
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
[TBL] [Abstract][Full Text] [Related]
34. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study.
Shi JW; Zhou Y; Wu S
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10472-10480. PubMed ID: 37975371
[TBL] [Abstract][Full Text] [Related]
36. Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis.
Diniz TP; da Costa WL; Fonseca de Jesus VH; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Torres SM; Felismino TC; Coimbra FJF
J Surg Oncol; 2020 Apr; 121(5):823-832. PubMed ID: 31950511
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
38. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
[TBL] [Abstract][Full Text] [Related]
39. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
Zhang XL; Shi HJ; Cui SZ; Tang YQ; Ba MC
Eur J Surg Oncol; 2011 Jun; 37(6):466-72. PubMed ID: 21414740
[TBL] [Abstract][Full Text] [Related]
40. Retrospective evaluation of the efficacy of first-line treatment of advanced gastric cancer with docetaxel and oxaliplatin.
Mao ZY; Guo XC; Su D; Wang LJ; Zhang TT; Bai L
Cancer Invest; 2015 Jan; 33(1):16-21. PubMed ID: 25495414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
